(HealthDay News) — The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist ...
According to the Company, the generic product will launch immediately. The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ®. Liraglutide is ...
Generic Saxenda ® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market. This approval and launch add to Teva’s ...
Hikma recently received the Food and Drug Administration’s permission for a new generic, and the company also launched two new generic products. The FDA approved Hikma's first generic referencing ...
In a global move, Indian pharmaceutical company, Lupin on Friday has launched a generic diabetes medication in the US market. It has launched Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient ...
The FDA approved the first-ever generic form of a GLP-1 receptor agonist specifically indicated for weight loss, Teva Pharmaceuticals announced Thursday. The generic form of liraglutide (Saxenda) is ...
Approval of the once-daily injection, as an adjunct to diet and exercise, is intended to help with drug shortages and improve patient access. (HealthDay News) — The US Food and Drug Administration has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results